{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:18Z","timestamp":1791605838854,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01118-9","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:34:09Z","timestamp":1773200049000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["C-reactive protein and residual cardiovascular risk in hypertension: a prospective cohort study"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-5881","authenticated-orcid":false,"given":"Anping","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-4937","authenticated-orcid":false,"given":"Aletta E.","family":"Schutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-7439","authenticated-orcid":false,"given":"Gianfranco","family":"Parati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u201380.","journal-title":"Lancet"},{"key":"1118_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"MH Forouzanfar","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. Jama. 2017;317:165\u201382.","journal-title":"Jama"},{"key":"1118_CR3","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13\u2013e115.","journal-title":"Hypertension"},{"key":"1118_CR4","doi-asserted-by":"crossref","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension (Dallas, Tex. : 1979) 2020: Hypertensionaha12015026.","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"1118_CR5","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia Chairperson","year":"2023","unstructured":"Mancia Chairperson G, Kreutz Co-Chair R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J hypertension. 2023;41:1874\u20132071.","journal-title":"J hypertension"},{"key":"1118_CR6","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","volume":"374","author":"EM Lonn","year":"2016","unstructured":"Lonn EM, Bosch J, L\u00f3pez-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009\u201320.","journal-title":"N Engl J Med"},{"key":"1118_CR7","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists' Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625\u201336.","journal-title":"Lancet"},{"key":"1118_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.7326\/M14-0773","volume":"162","author":"J Sundstr\u00f6m","year":"2015","unstructured":"Sundstr\u00f6m J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162:184\u201391.","journal-title":"Ann Intern Med"},{"key":"1118_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.123.22610","volume":"81","author":"E Manta","year":"2024","unstructured":"Manta E, Thomopoulos C, Kariori M, Polyzos D, Mihas C, Konstantinidis D, et al. Revisiting cardiovascular benefits of blood pressure reduction in primary and secondary prevention: focus on targets and residual risk-a systematic review and meta-analysis. Hypertension. 2024;81:1076\u201386.","journal-title":"Hypertension"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/jhh.2013.111","volume":"28","author":"FG Hage","year":"2014","unstructured":"Hage FG. C-reactive protein and hypertension. J Hum hypertension. 2014;28:410\u20135.","journal-title":"J Hum hypertension"},{"key":"1118_CR11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","volume":"67","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiology. 2016;67:712\u201323.","journal-title":"J Am Coll Cardiology"},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1161\/01.CIR.0000136581.59584.0E","volume":"110","author":"MK Rutter","year":"2004","unstructured":"Rutter MK, Meigs JB, Sullivan LM, D\u2019Agostino RB Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the framingham offspring study. Circulation. 2004;110:380\u20135.","journal-title":"Circulation"},{"key":"1118_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/CIRCULATIONAHA.104.504159","volume":"112","author":"M Cushman","year":"2005","unstructured":"Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112:25\u201331.","journal-title":"Circulation"},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamacardio.2019.0179","volume":"4","author":"P Mani","year":"2019","unstructured":"Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP, et al. Association of initial and serial C-Reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 Trial. JAMA cardiology. 2019;4:314\u201320.","journal-title":"JAMA cardiology"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/eurjpc\/zwaa052","volume":"29","author":"Z Chen","year":"2022","unstructured":"Chen Z, Mo J, Xu J, Wang A, Dai L, Cheng A, et al. Effects of individual and integrated cumulative burden of blood pressure, glucose, low-density lipoprotein cholesterol, and C-reactive protein on cardiovascular risk. Eur J preventive cardiology. 2022;29:127\u201335.","journal-title":"Eur J preventive cardiology"},{"key":"1118_CR16","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","volume":"359","author":"J Zacho","year":"2008","unstructured":"Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"1118_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2009.954","volume":"302","author":"P Elliott","year":"2009","unstructured":"Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. Jama. 2009;302:37\u201348.","journal-title":"Jama"},{"key":"1118_CR18","doi-asserted-by":"publisher","first-page":"d548","DOI":"10.1136\/bmj.d548","volume":"342","author":"F Wensley","year":"2011","unstructured":"Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.","journal-title":"BMJ"},{"key":"1118_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29650-5","volume":"13","author":"S Said","year":"2022","unstructured":"Said S, Pazoki R, Karhunen V, V\u00f5sa U, Ligthart S, Bodinier B, et al. Genetic analysis of over half a million people characterises C-reactive protein loci. Nat Commun. 2022;13:2198.","journal-title":"Nat Commun"},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1001\/jama.290.22.2945","volume":"290","author":"HD Sesso","year":"2003","unstructured":"Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. Jama. 2003;290:2945\u201351.","journal-title":"Jama"},{"key":"1118_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/01.HYP.0000252664.24294.ff","volume":"49","author":"HD Sesso","year":"2007","unstructured":"Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension. 2007;49:304\u201310.","journal-title":"Hypertension"},{"key":"1118_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/jch.13510","volume":"21","author":"Y Kansui","year":"2019","unstructured":"Kansui Y, Matsumura K, Morinaga Y, Inoue M, Kiyohara K, Ohta Y, et al. C-reactive protein and incident hypertension in a worksite population of Japanese men. J Clin hypertension. 2019;21:524\u201332.","journal-title":"J Clin hypertension"},{"key":"1118_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/heartjnl-2018-314216","volume":"105","author":"A Jayedi","year":"2019","unstructured":"Jayedi A, Rahimi K, Bautista LE, Nazarzadeh M, Zargar MS, Shab-Bidar S. Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies. Heart. 2019;105:686\u201392.","journal-title":"Heart"},{"key":"1118_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/hr.2012.89","volume":"35","author":"H Kong","year":"2012","unstructured":"Kong H, Qian YS, Tang XF, Zhang J, Gao PJ, Zhang Y, et al. C-reactive protein (CRP) gene polymorphisms, CRP levels and risk of incident essential hypertension: findings from an observational cohort of Han Chinese. Hypertension Res. 2012;35:1019\u201323.","journal-title":"Hypertension Res"},{"key":"1118_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002073","volume":"4","author":"MC Jim\u00e9nez","year":"2015","unstructured":"Jim\u00e9nez MC, Rexrode KM, Glynn RJ, Ridker PM, Gaziano JM, Sesso HD. Association between high-sensitivity C-reactive protein and total stroke by hypertensive status among men. J Am Heart Assoc. 2015;4:e002073.","journal-title":"J Am Heart Assoc"},{"key":"1118_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.919506","volume":"10","author":"X Chen","year":"2022","unstructured":"Chen X, Liu S, Chu J, Hu W, Sun N, Shen Y. Joint effect of elevated-c-reactive protein level and hypertension on new-onset stroke: a nationwide prospective cohort study of CHARLS. Front public health. 2022;10:919506.","journal-title":"Front public health"},{"key":"1118_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2020.10.071","volume":"326","author":"S Kurl","year":"2021","unstructured":"Kurl S, Jae SY, Voutilainen A, M\u00e4kikallio T, Laukkanen JA. Joint effect of blood pressure and C-reactive protein and the risk of sudden cardiac death: a prospective cohort study. Int J cardiology. 2021;326:184\u20138.","journal-title":"Int J cardiology"},{"key":"1118_CR28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41440-019-0293-8","volume":"42","author":"HH Liu","year":"2019","unstructured":"Liu HH, Cao YX, Sun D, Jin JL, Zhang HW, Guo YL, et al. High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. Hypertension Res. 2019;42:1783\u201393.","journal-title":"Hypertension Res"},{"key":"1118_CR29","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/01.CIR.0000104566.10178.AF","volume":"108","author":"GJ Blake","year":"2003","unstructured":"Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993\u20139.","journal-title":"Circulation"},{"key":"1118_CR30","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.","journal-title":"PLoS Med"},{"key":"1118_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"1118_CR32","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195\u2013207.","journal-title":"N Engl J Med"},{"key":"1118_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"1118_CR34","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/eurjpc\/zwad116","volume":"30","author":"C Liu","year":"2023","unstructured":"Liu C, Li C. C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs. Eur J preventive cardiology. 2023;30:1593\u20136.","journal-title":"Eur J preventive cardiology"},{"key":"1118_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1373\/clinchem.2008.117754","volume":"55","author":"J Shen","year":"2009","unstructured":"Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin Chem. 2009;55:256\u201364.","journal-title":"Clin Chem"},{"key":"1118_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/01.CIR.100.1.96","volume":"100","author":"WK Lagrand","year":"1999","unstructured":"Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96\u2013102.","journal-title":"Circulation"},{"key":"1118_CR37","doi-asserted-by":"publisher","first-page":"e0184914","DOI":"10.1371\/journal.pone.0184914","volume":"12","author":"M Tibuakuu","year":"2017","unstructured":"Tibuakuu M, Kamimura D, Kianoush S, DeFilippis AP, Al Rifai M, Reynolds LM, et al. The association between cigarette smoking and inflammation: the genetic epidemiology network of arteriopathy (GENOA) study. PLoS one. 2017;12:e0184914.","journal-title":"PLoS one"},{"key":"1118_CR38","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","volume":"282","author":"M Visser","year":"1999","unstructured":"Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. Jama. 1999;282:2131\u20135.","journal-title":"Jama"},{"key":"1118_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1161\/01.CIR.0000045669.16499.EC","volume":"107","author":"MA Albert","year":"2003","unstructured":"Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation. 2003;107:443\u20137.","journal-title":"Circulation"},{"key":"1118_CR40","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/ajcn\/84.6.1489","volume":"84","author":"A Esmaillzadeh","year":"2006","unstructured":"Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. Am J Clin Nutr. 2006;84:1489\u201397.","journal-title":"Am J Clin Nutr"},{"key":"1118_CR41","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.3390\/molecules26113369","volume":"26","author":"G Costabile","year":"2021","unstructured":"Costabile G, Della Pepa G, Vetrani C, Vitaglione P, Griffo E, Giacco R, et al. An oily fish diet improves subclinical inflammation in people at high cardiovascular risk: a randomized controlled study. Molecules. 2021;26:3369.","journal-title":"Molecules"},{"key":"1118_CR42","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","volume":"25","author":"C Arnaud","year":"2005","unstructured":"Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, et al. Statins reduce interleukin-6\u2013induced C-Reactive protein in human hepatocytes. Arterioscler Thromb Vasc Biol. 2005;25:1231\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1118_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","volume":"141","author":"PM Ridker","year":"2020","unstructured":"Ridker PM. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020;141:787\u20139.","journal-title":"Circulation"},{"key":"1118_CR44","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","volume":"72","author":"PM Ridker","year":"2018","unstructured":"Ridker PM. Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiology. 2018;72:3320\u201331.","journal-title":"J Am Coll Cardiology"},{"key":"1118_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jacc.2023.05.035","volume":"82","author":"PM Burger","year":"2023","unstructured":"Burger PM, Koudstaal S, Mosterd A, Fiolet ATL, Teraa M, van der Meer MG, et al. C-Reactive protein and risk of incident heart failure in patients with cardiovascular disease. J Am Coll Cardiology. 2023;82:414\u201326.","journal-title":"J Am Coll Cardiology"},{"key":"1118_CR46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","volume":"375","author":"S Kaptoge","year":"2010","unstructured":"Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132\u201340.","journal-title":"Lancet"},{"key":"1118_CR47","doi-asserted-by":"publisher","first-page":"dyae054","DOI":"10.1093\/ije\/dyae054","volume":"53","author":"S van Alten","year":"2024","unstructured":"van Alten S, Domingue BW, Faul J, Galama T, Marees AT. Reweighting UK Biobank corrects for pervasive selection bias due to volunteering. Int J Epidemiol. 2024;53:dyae054.","journal-title":"Int J Epidemiol"},{"key":"1118_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/CP9.0000000000000097","volume":"9","author":"H Amirfakhryan","year":"2024","unstructured":"Amirfakhryan H, New KJ. The role of myeloperoxidase as a biomarker in atherosclerotic cardiovascular disease. Cardiology Plus. 2024;9:195\u2013209.","journal-title":"Cardiology Plus"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01118-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:02:26Z","timestamp":1775847746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01118-9","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The project has approval from the North West Multi-center Research Ethics Committee (MREC) (REC reference 21:\/NW\/0157), and informed written consent was obtained from each participant. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}